Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy

The results of recent studies investigating the role of platinum-based chemotherapy (PBCT) in metastatic triple-negative breast cancer (mTNBC) were conflicting. We retrospectively investigated a large cohort (n = 379) of mTNBC to re-evaluate the role of platinums. Longer PFS was found in patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jian, Fan, Minhao, Xie, Jie, Wang, Zhonghua, Wang, Biyun, Zhang, Sheng, Wang, Leiping, Cao, Jun, Tao, Zhonghua, Li, Ting, Hu, Xichun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4767497/
https://www.ncbi.nlm.nih.gov/pubmed/26447756
_version_ 1782417827960979456
author Zhang, Jian
Fan, Minhao
Xie, Jie
Wang, Zhonghua
Wang, Biyun
Zhang, Sheng
Wang, Leiping
Cao, Jun
Tao, Zhonghua
Li, Ting
Hu, Xichun
author_facet Zhang, Jian
Fan, Minhao
Xie, Jie
Wang, Zhonghua
Wang, Biyun
Zhang, Sheng
Wang, Leiping
Cao, Jun
Tao, Zhonghua
Li, Ting
Hu, Xichun
author_sort Zhang, Jian
collection PubMed
description The results of recent studies investigating the role of platinum-based chemotherapy (PBCT) in metastatic triple-negative breast cancer (mTNBC) were conflicting. We retrospectively investigated a large cohort (n = 379) of mTNBC to re-evaluate the role of platinums. Longer PFS was found in patients with PBCT than those with non-PBCT (7.8 vs. 4.9 months, P < 0.001) as first-line chemotherapy, but no statistical difference of OS was observed. Compared with other kinds of platinum, cisplatin-based regimens as the first-line chemotherapy showed better PFS (8.0 vs. 4.3 months, P = 0.03) and better ORR. Introduction of ≥2 lines, rather than 1 line, of PBCT can result in better OS when compared with no introduction of PBCT during the whole treatment. If considering the timing of intervention of PBCT, first-line introduction and later line introduction of PBCT did not make any difference in OS among patients with only one line PBCT during the whole treatment. We concluded that PBCT with only 1 line during the whole treatment might not be necessary for unselected mTNBC with the exception of an urgent demand to control disease or symptoms, however, ≥2 lines of PBCT did prolong OS.
format Online
Article
Text
id pubmed-4767497
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-47674972016-03-25 Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy Zhang, Jian Fan, Minhao Xie, Jie Wang, Zhonghua Wang, Biyun Zhang, Sheng Wang, Leiping Cao, Jun Tao, Zhonghua Li, Ting Hu, Xichun Oncotarget Clinical Research Paper The results of recent studies investigating the role of platinum-based chemotherapy (PBCT) in metastatic triple-negative breast cancer (mTNBC) were conflicting. We retrospectively investigated a large cohort (n = 379) of mTNBC to re-evaluate the role of platinums. Longer PFS was found in patients with PBCT than those with non-PBCT (7.8 vs. 4.9 months, P < 0.001) as first-line chemotherapy, but no statistical difference of OS was observed. Compared with other kinds of platinum, cisplatin-based regimens as the first-line chemotherapy showed better PFS (8.0 vs. 4.3 months, P = 0.03) and better ORR. Introduction of ≥2 lines, rather than 1 line, of PBCT can result in better OS when compared with no introduction of PBCT during the whole treatment. If considering the timing of intervention of PBCT, first-line introduction and later line introduction of PBCT did not make any difference in OS among patients with only one line PBCT during the whole treatment. We concluded that PBCT with only 1 line during the whole treatment might not be necessary for unselected mTNBC with the exception of an urgent demand to control disease or symptoms, however, ≥2 lines of PBCT did prolong OS. Impact Journals LLC 2015-10-03 /pmc/articles/PMC4767497/ /pubmed/26447756 Text en Copyright: © 2015 Zhang et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Clinical Research Paper
Zhang, Jian
Fan, Minhao
Xie, Jie
Wang, Zhonghua
Wang, Biyun
Zhang, Sheng
Wang, Leiping
Cao, Jun
Tao, Zhonghua
Li, Ting
Hu, Xichun
Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy
title Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy
title_full Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy
title_fullStr Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy
title_full_unstemmed Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy
title_short Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy
title_sort chemotherapy of metastatic triple negative breast cancer: experience of using platinum-based chemotherapy
topic Clinical Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4767497/
https://www.ncbi.nlm.nih.gov/pubmed/26447756
work_keys_str_mv AT zhangjian chemotherapyofmetastatictriplenegativebreastcancerexperienceofusingplatinumbasedchemotherapy
AT fanminhao chemotherapyofmetastatictriplenegativebreastcancerexperienceofusingplatinumbasedchemotherapy
AT xiejie chemotherapyofmetastatictriplenegativebreastcancerexperienceofusingplatinumbasedchemotherapy
AT wangzhonghua chemotherapyofmetastatictriplenegativebreastcancerexperienceofusingplatinumbasedchemotherapy
AT wangbiyun chemotherapyofmetastatictriplenegativebreastcancerexperienceofusingplatinumbasedchemotherapy
AT zhangsheng chemotherapyofmetastatictriplenegativebreastcancerexperienceofusingplatinumbasedchemotherapy
AT wangleiping chemotherapyofmetastatictriplenegativebreastcancerexperienceofusingplatinumbasedchemotherapy
AT caojun chemotherapyofmetastatictriplenegativebreastcancerexperienceofusingplatinumbasedchemotherapy
AT taozhonghua chemotherapyofmetastatictriplenegativebreastcancerexperienceofusingplatinumbasedchemotherapy
AT liting chemotherapyofmetastatictriplenegativebreastcancerexperienceofusingplatinumbasedchemotherapy
AT huxichun chemotherapyofmetastatictriplenegativebreastcancerexperienceofusingplatinumbasedchemotherapy